Acquired bleeding disorders.

Autor: Tiede A; Department of Haematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany., Susen S; Hemostasis and Transfusion Department, University of Lille, Lille University Hospital, Lille, France., Lisman T; Surgical Research Laboratory and Section of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.
Jazyk: afrikánština
Zdroj: Haemophilia : the official journal of the World Federation of Hemophilia [Haemophilia] 2024 Apr; Vol. 30 Suppl 3, pp. 29-38. Date of Electronic Publication: 2024 Apr 02.
DOI: 10.1111/hae.14995
Abstrakt: Acquired bleeding disorders can develop in previously healthy people irrespective of age or gender but are particularly common in patients with certain underlying conditions. Here, we review recent advances in the management of acquired haemophilia A (AHA), acquired von Willebrand syndrome (AVWS), and patients with hemostatic abnormalities due to chronic liver disease (CLD). Patients with AHA can now benefit from prophylaxis with emicizumab, a therapeutic antibody that mimics the function of activated coagulation factor VIII. The treatment of AVWS remains challenging in many situations and requires careful consideration of the underlying condition. Haemostatic abnormalities in CLD are often compensated by proportional reduction in pro and anti-haemostatic factors resulting in sustained or even increased thrombin generation. Consequently, bleeding in CLD is rarely caused by haemostatic failure and infusion of plasma or coagulation factor concentrates may not be effective.
(© 2024 John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: